Regeneron Pharmaceuticals Company Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Country | United States |
Founded | 1988 |
Industry | Medical - Pharmaceuticals |
Sector | Healthcare |
Employees | 13,450 |
CEO | Leonard Schleifer |
Contact Details
Address: 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 United States | |
Phone | 914 847 7000 |
Website | regeneron.com |
Stock Details
Ticker Symbol | 0R2M |
Exchange | London Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | USD |
ISIN Number | US75886F1075 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Leonard Schleifer | Chief Executive Officer |
Christopher Fenimore | Chief Financial Officer |
Patrice Gilooly | Chief Operating Officer |
Ryan Crowe | Head of Investor Relations |